Despite many recent advances in its management, type 1 diabetes remains a burden for those living with the condition.
Prof. Chantal Mathieu explains the progress being made with disease-modifying therapy for type 1 diabetes and how it has the potential to transform the current treatment landscape.
« Previous episode: The gut microbiome and CAR T-cell therapy
Further reading
- Ramos EL, Dayan CM, Chatenoud L, et al. Teplizumab and β-cell function in newly diagnosed type 1 diabetes. N Engl J Med 2023; 389: 2151–2161.
- Herold KC, Bundy BN, Long SA et al. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med 2019; 381: 603–613.
- Mathieu C, Wiedeman A, Cerosaletti K, et al. A first-in-human, open-label Phase 1b and a randomised, double-blind Phase 2a clinical trial in recent-onset type 1 diabetes with AG019 as monotherapy and in combination with teplizumab. Diabetologia 2024; 67: 27–41.
- Waibel M, Wentworth JM, Michelle So, et al. Baricitinib and β-cell function in patients with new-onset type 1 diabetes. N Engl J Med 2023; 389: 2140–2150.
- https://www.innodia.org/
- https://www.edent1fi.eu/